This is consistent with laboratory observations where wildtype hematopoietic stem/progenitor cells had a competitive advantage over RPS19 haploinsufficient cells in mouse and human cell models of DBA, providing rationale for use of RIC regimens (18, 59). Here, RPS19 is linked to Diamond-Blackfan anemia.